IL27 and cancer: A human monoclonal (IgG1) antibody against the IL-27p28 subunit CHS388 (former SRF388), that blocks IL-27/IL-27RA interaction is under consideration for cancer treatment, where a Phase I study has already been shown to be safe in humans (1, 154–158).